155 related articles for article (PubMed ID: 36709123)
1. [Single-center study of different treatment for advanced or unresectable angiosarcoma patients].
Peng RQ; Xu BS; Liu YY; Yang QQ; Pan QZ; Zhang X
Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):74-81. PubMed ID: 36709123
[No Abstract] [Full Text] [Related]
2. PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis.
Wang F; Wang FH; Sun K; Jiang C; Peng S; Xu LX; Kuang M; Guo GF; Chen SL
J Inflamm Res; 2022; 15():6031-6046. PubMed ID: 36339826
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.
Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S
Front Immunol; 2023; 14():1278573. PubMed ID: 38124737
[TBL] [Abstract][Full Text] [Related]
4. Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment.
Park C; Kim M; Kwak Y; Moon KC; Kim SH; Keam B; Kim YJ; Kim TM; Kim DW
Cancer Res Treat; 2021 Oct; 53(4):1195-1203. PubMed ID: 33540493
[TBL] [Abstract][Full Text] [Related]
5. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy.
Fury MG; Antonescu CR; Van Zee KJ; Brennan MF; Maki RG
Cancer J; 2005; 11(3):241-7. PubMed ID: 16053668
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
[TBL] [Abstract][Full Text] [Related]
7. The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian Sarcoma Consortium.
Chen TW; Pang A; Puhaindran ME; Maw MM; Loong HH; Sriuranpong V; Chang CC; Mingmalairak S; Hirose T; Endo M; Kawai A; Farid M; Tan SH; Goh WL; Quek R; Chan JCH; Leung AKC; Ngan RKC
Cancer Sci; 2021 Mar; 112(3):1095-1104. PubMed ID: 33393133
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis.
Zhao L; Zhao Z; Yan X; Wu F; Sun N; Guo R; Yu S; Hu X; Feng J
Int J Clin Pract; 2024; 2024():8585035. PubMed ID: 38375028
[TBL] [Abstract][Full Text] [Related]
9. [A real-world study on the efficacy and safety analysis of paclitaxel liposome in advanced breast cancer].
Sun CX; Wang SS; Li JB; Wang YS; Ouyang QC; Yang J; Wang HB; Wang XJ; Chen WY; Yuan P; Yan M; Jiang ZF; Yin YM
Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):88-94. PubMed ID: 36709125
[No Abstract] [Full Text] [Related]
10. Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis.
Zhao L; Zhao Z; Yan X; Hu X; Feng J; Yu S
Technol Cancer Res Treat; 2024; 23():15330338241227055. PubMed ID: 38258375
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Kong Q; Wang XY; Jiang RC; Ba Y; Li K
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma.
Skubitz KM; Haddad PA
Cancer; 2005 Jul; 104(2):361-6. PubMed ID: 15948172
[TBL] [Abstract][Full Text] [Related]
13. [Clinical Observation of Immunotherapy Efficacy and Adverse Effects
in Chinese Patients with Lung Squamous Cell Carcinoma].
Yu J; Wu X; Ma J; Chen X; Li L
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):546-554. PubMed ID: 35899455
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.
Jones RL; Ravi V; Brohl AS; Chawla S; Ganjoo KN; Italiano A; Attia S; Burgess MA; Thornton K; Cranmer LD; Cheang MCU; Liu L; Robertson L; Adams B; Theuer C; Maki RG
JAMA Oncol; 2022 May; 8(5):740-747. PubMed ID: 35357396
[TBL] [Abstract][Full Text] [Related]
15. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
[TBL] [Abstract][Full Text] [Related]
16. Third-line treatment options in metastatic pancreatic cancer patients: a real-world study.
Lu HR; Zhu PF; Deng YY; Chen ZL; Yang L
Front Oncol; 2023; 13():1251258. PubMed ID: 37810973
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
Wagner MJ; Othus M; Patel SP; Ryan C; Sangal A; Powers B; Budd GT; Victor AI; Hsueh CT; Chugh R; Nair S; Leu KM; Agulnik M; Sharon E; Mayerson E; Plets M; Blanke C; Streicher H; Chae YK; Kurzrock R
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34380663
[TBL] [Abstract][Full Text] [Related]
20. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
